| Title |
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2012
|
| DOI | 10.2147/dddt.s25757 |
| Pubmed ID | |
| Authors |
Lindsay S Keir, Stephen D Marks, Jon Jin Kim |
| Abstract |
Hemolytic uremic syndrome is the leading cause of acute kidney injury in childhood. Ninety percent of cases are secondary to gastrointestinal infection with shigatoxin-producing bacteria. In this review, we discuss the molecular mechanisms of shigatoxin leading to hemolytic uremic syndrome and the emerging role of the complement system and vascular endothelial growth factor in its pathogenesis. We also review the evidence for treatment options to date, in particular antibiotics, plasma exchange, and immunoadsorption, and link this to the molecular pathology. Finally, we discuss future avenues of treatment, including shigatoxin-binding agents and complement inhibitors, such as eculizumab. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| United Kingdom | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 102 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 17% |
| Student > Master | 17 | 16% |
| Researcher | 14 | 13% |
| Student > Ph. D. Student | 10 | 9% |
| Other | 9 | 8% |
| Other | 24 | 23% |
| Unknown | 14 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 45% |
| Agricultural and Biological Sciences | 24 | 23% |
| Biochemistry, Genetics and Molecular Biology | 7 | 7% |
| Immunology and Microbiology | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 4 | 4% |
| Unknown | 15 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2013.
All research outputs
#20,688,303
of 25,411,814 outputs
Outputs from Drug Design, Development and Therapy
#1,440
of 2,271 outputs
Outputs of similar age
#138,291
of 176,804 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 4 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,271 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,804 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.